Vaibhav Sahai, MBBS, MS

Vaibhav Sahai
Lindsay Olson Pancreatic Cancer Research Professor
Associate Professor of Internal Medicine
Medical School
University of Michigan Medical School
Department of Internal Medicine
1500 E. Medical Center Drive
Ann Arbor, MI 48109
Available to mentor
Vaibhav Sahai, MBBS, MS
Vaibhav Sahai
Associate Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • Manage Your Profile

  • Qualifications

    • Chief Fellow
      Northwestern University, Internal Medicine - Hematology and Oncology, Evanston, United States
      2012 - 2013
      Chief Fellow
    • Fellow
      Northwestern University, Internal Medicine - Hematology and Oncology, Evanston, United States
      2010 - 2012
      Clinical Fellowship
    • Resident
      University of Pittsburgh Medical Center, Internal Medicine, Pittsburgh, United States
      2007 - 2010
      Residency
    • Postdoctoral Fellow
      Harvard Medical School, Radiology, Boston, United States
      2006 - 2007
      Postdoctoral Fellowship
    • Diploma
      Bioinformatics Institute of India Noida, Medical Informatics, Noida, Noida, India, India
      2004 - 2005
      Other
    • MS
      Harvard School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, United States
      2005 - 2006
    • MB BS
      Government Medical College, One Circular Road, Amritsar, Punjab, India, 143001, India
      1998 - 2004

    Center Memberships

    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Rogel Cancer Center

    Research Overview

    The focus of my research lies in experimental therapeutics in pancreaticobiliary cancers via a molecular-based approach in the laboratory. As the Lindsay Olson Pancreatic Cancer Research Professor and Section Head of Gastrointestinal Oncology in the Division of Hematology and Oncology, I am privileged to see patients within the multidisciplinary pancreatic and liver tumor programs. As a tenured clinical and translational researcher, I specialize in the design, implementation, and execution of investigator-initiated and sponsored phase 1/2 clinical trials to investigate novel compounds in patients with pancreas and biliary cancers based on pre-clinical investigation conducted either in my lab or as team science projects. As the Director of Pancreaticobiliary biobanks at the Rogel Cancer Center my translational lab generates and uses organoid models for the therapeutic investigation of novel compounds in pancreaticobiliary cancers. Additionally, I have an imaging lab with focus on imaging software development and research in morphomics and radiomics in pancreaticobiliary cancers. As the Founding Director of the Tumor Response Assessment Core (TRAC) my lab provides standardized, precision imaging metrics for patients enrolled on clinical trials at the Rogel Cancer Center.

    Recent Publications

    See All Publications
    • Preprint
      A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer
      Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM. 2026 Jun 21; bioRxiv, DOI:10.64898/2026.06.15.732391
    • Journal Article
      MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.
      Bao YL, Guo Y, de Castria TB, Boland PM, Toegel EB, Fishel M, Cavnar MJ, Fountzilas C, Chan CHF, Rehman M, Salhia B, Gage MM, Hatoum H, Rounbehler RJ, Churchman ML, Yang W, Sahai V, Malla M, Manne U, Manne A. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 4194 - 4194. DOI:10.1200/jco.2026.44.16_suppl.4194
    • Journal Article
      296b LONGITUDINAL ANALYSIS OF MATCHED PATIENT BIOSPECIMENS REVEALS NEURAL REPROGRAMMING OF CANCER-ASSOCIATED FIBROBLASTS FOLLOWING CHEMOTHERAPY IN PANCREATIC DUCTAL ADENOCARCINOMA
      Henstridge A, Sahai V, Peterson N, Machicado JD, Kwon R, Schulman AR, Wamsteker E-J, Philips GM, Menees SB, Xia JY, Hogenson T, Shi J, Frankel T, Bednar F, Di Magliano MP, Lyssiotis CA, Truty MJ, Fernandez-Zapico ME, Carpenter E. Gastroenterology, 2026 May 7; 170 (6): s - 2850. DOI:10.1016/s0016-5085(26)06741-7
    • Journal Article
      Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.
      Li C, Ke F, Zhao H, Mao S, Djibo M, Huang L, He M, Wang M, Wen H, Liu Z, Yu Z, Qi Z, Xavier AR, Nenwani M, Wen B, Peterson N, Sahai V, Nagrath D, Lucas CL, Wymann MP, Gao W, Fong L, Sun D. Nat Cancer, 2026 Apr 28; DOI:10.1038/s43018-026-01158-7
      PMID: 42049931
    • Journal Article
      Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
      Mahalingam D, Shroff RT, Carneiro BA, Ji Y, Coveler AL, Cervantes A, Sahai V, Ploquin A, Hiret S, LoConte NK, Percent IJ, Lopez CD, Pernot S, Kavan P, Mulcahy M, Carr R, Giles FJ, Seifarth C, Ugolkov A, Weiskittel T, Fine G, Jaros M, Mazar AP, Bekaii-Saab TS. Nat Med, 2026 Apr 14; DOI:10.1038/s41591-026-04327-4
      PMID: 41981308
    • Proceeding / Abstract / Poster
      Abstract 1043: MUC5AC expression defines an immune-inflamed but functionally restrained tumor microenvironment in pancreatic ductal adenocarcinoma
      Manne A, Yang W, Guo Y, Sahai V, Bajpai P, Bao Y, Khan Niazi MK, Leyva A, Manne U. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 1043 - 1043. DOI:10.1158/1538-7445.am2026-1043
    • Proceeding / Abstract / Poster
      Abstract 1313: Circulating tumor cell (CTC) informed pipeline for rapid personalization of synergistic cytokine-armed CAR-NK cell therapy in PDAC.
      Zou Y, Tarannum M, Fouladdel S, Zhang Y, Peterson N, Sahai V, Nagrath D, Romee R, Nagrath S. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 1313 - 1313. DOI:10.1158/1538-7445.am2026-1313
    • Proceeding / Abstract / Poster
      Dual inhibition of PIKfyve and FASN reveals therapeutic potential in neuroendocrine prostate cancer
      Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu JH, Mannan R, Karaburk H, Bhattacharyya R, Yin Y, Cao X, Xue H, Li C, Wang Z, Miner S, Vaishampayan UN, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM. Cancer Research, 2026 Apr 17; 86 (7):